Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women

Journal of Clinical Pharmacology

Volumn 46, Issue 1, 2006, Pages 52-58

  Gardner, Mark ^a   Taylor, Ann ^a   Wei, Greg ^a   Calcagni Jr , Albert ^a   Duncan, Barbara ^a   Milton, Ashley ^a  

^a PFIZER INC   (United States)

Author keywords

Lasofoxifene; Osteoporosis; Pharmacodynamics; Pharmacokinetics; Pharmacology

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CHOLESTEROL; FOLLITROPIN; LASOFOXIFENE; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MULTIPLE DRUG DOSE; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; CHOLESTEROL, LDL; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; PEPTIDES; POSTMENOPAUSE; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES;

EID: 29644446214     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005283280     Document Type: Article

References (25)

1. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. Washington, DC: National Osteoporosis Foundation; 2002.
2. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol. 1996;10:119-131.
3. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol. 1995;9:659-669.
4. Pandian MR, Odell WD, Carlton E, Fisher DA. Development of third-generation immunochemiluminometric assays of follitropin and lutropin and clinical application in determining pediatric reference ranges. Clin Chem. 1993;39:1815-1819.
5. Jarausch J. Evaluation of two assays for the direct determination of HDL and LDL cholesterol [abstract]. Presented at: Elsevier Science. Atherosclerosis. 1997;130(suppl 1):13-13(1).
6. Panigrahi K, Delmas PD, Singer F, et al. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem. 1994;40:822-828.
7. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 1992;7:1251-1258.
8. Eppenberger U, Wosikowski K, Kung W. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol. 1991;14(suppl 2):S5-S14.
9. Bryant HU, Glasebrook AL, Yang NN, Sato M. A pharmacological review of raloxifene. J Bone Min Metab. 1996;14:1-9.
10. Ke HZ, Thompson DD. Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies. J Amer Aging Assoc. 2002;25:87-100.
11. Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology. 1998;139:2068-2076.
12. Rosati RL, Silva Jardine P, Cameron K, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem. 1998;41:2928-2931.
13. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003;42:361-372.
14. Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm. 2000;57:1669-1675.
15. Raloxifene [prescribing information]. Indianapolis, Ind: Eli Lilly and Company; 2003.
16. Bolognese M, Weiss S, Ettinger M, Moffett AJ, Lee A. Lasofoxifene: a next generation selective estrogen receptor modulator (SERM) for the prevention of bone loss in postmenopausal women [abstract]. Osteoporos Int. 2004;15(suppl 1):S11.
17. Ettinger M, Schwartz E, Emkey R, et al. Lasofoxifene, a next generation selective estrogen receptor modulator (SERM), in the prevention of bone loss in postmenopausal women (S35-2). Presented at: ENDO; June 16-19, 2004; New Orleans, La. Abstract #S35-2.
18. Ebeling PR, Atley LM, Guthrie JR, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab. 1996;81:3366-3371.
19. Rosen CJ, Chesnut CH III, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 1997;82:1904-1910.
20. Prestwood KM, Pilbeam CC, Burleson JA, et al. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab. 1994;79:366-371.
21. Prestwood KM, Kenny AM, Unson C, Kulldorff M. The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab. 2000;85:4462-4469.
22. Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab. 2000;85:2197-2202.
23. Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA. 2001;286:815-820.
24. Miller BE, De Souza MJ, Slade K, Luciano AA. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density. Menopause. 2000;7:318-326.
25. McClung M, Omizo M, Weiss S, et al. Comparison of lasofoxifene and raloxifene for the prevention of bone loss in postmenopausal women [abstract]. J Bone Miner Res. 2004;19(suppl 1):S96. F424.